Oncogenic c-kit transcript is a target for binase

Cell Cycle

Volumn 9, Issue 13, 2010, Pages 2674-2678

  Mitkevich, Vladimir A ^a   Petrushanko, Irina Yu ^a   Kretova, Olga V ^a   Spirin, Pavel V ^a   Zelenikhin, Pavel V ^b   Prassolov, Vladimir S ^a   Tchurikov, Nickolai A ^a   Ilinskaya, Olga N ^a,b   Makarov, Alexander A ^a  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b KAZAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

Cellular RNA degradation; Cytotoxic RNase; Imatinib (gleevec); Interleukin; Mutated c Kit; Myeloid progenitor cells; Oncogene expression

Indexed keywords

BINASE; GREEN FLUORESCENT PROTEIN; IMATINIB; INTERLEUKIN 3; MESSENGER RNA; RIBONUCLEASE; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; ONCOGENE; POINT MUTATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL;

BACILLUS INTERMEDIUS;

EID: 77955437455     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.13.12150     Document Type: Article

References (32)

1. Wang Y-Y, Zhou G-B, Tong YT, Chen B, Shi J-Y, Liang W-X, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 2005; 102:1104-9.
2. Ilinskaya ON, Zelenikhin PV, Petrushanko IY, Mitkevich VA, Prassolov VS, Makarov AA. Binase induces apoptosis of transformed myeloid cells and does not induce T-cell immune response. Biochem Biophys Res Commun 2007; 361:1000-5.
3. Ilinskaya O, Decker K, Koschinski A, Dreyer F, Repp H. Bacillus intermedius ribonuclease as inhibitor of cell proliferation and membrane current. Toxicology 2001; 156:101-7.
4. Goemans BF, Zwaan CM, Miller M, Zimmermann M, Harlow A, Meshinchi S, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 2005; 19:1536-42.
5. Zermati Y, De Sepulveda P, Feger F, Letard S, Kersual J, Casteran N, et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003; 22:660-4.
6. Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009; 9:66-76.
7. Cammenga J, Horn S, Bergholz U, Sommer G, Besmer P, Fiedler W, Stocking C. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood 2005; 106:3958-61.
8. Matousek J. Ribonucleases and their antitumor activity. Comp Biochem Physiol C Toxicol Pharmacol 2001; 129:175-91.
9. Leland P, Raines R. Cancer chemotherapy: Ribonucleases to the rescue. Chem Biol 2001; 8:405-13.
10. Makarov AA, Ilinskaya ON. Cytotoxic ribonucleases: molecular weapons and their targets. FEBS Lett 2003; 540:15-20.
11. Makarov AA, Kolchinsky A, Ilinskaya ON. Binase and other microbial RNases as potential anticancer agents. BioEssays 2008; 30:781-90.
12. Ardelt W, Shogen K, Darzynkiewicz Z. Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes. Curr Pharm Biotechnol 2008; 9:215-25.
13. Antignani A, Naddeo M, Cubellis MV, Russo A, D'Alessio G. Antitumor action of seminal ribonuclease, its dimeric structure, and its resistance to the cytosolic ribonuclease inhibitor. Biochemistry 2001; 40:3492-6.
14. Olmo N, Turnay J, Gonzalez de Butitrago G, Lopez de Silanes I, Gavilanes JG, Lizarbe MA. Cytotoxic mechanism of the ribotoxin alpha-sarcin. Induction of cell death via apoptosis. Eur J Biochem 2001; 268:2113-23.
15. Lancaster LE, Wintermeyer W, Rodnina MV. Colicins and their potential in cancer treatment. Blood Cells Mol Dis 2007; 38:15-8.
16. Libonati M, Gotte G, Vottariello F. A novel biological action aquired by ribonuclease through oligomerization. Curr Pharm Biotechnol 2008; 9:200-9.
17. Songyang Z, Baltimore D, Cantley LC, Kaplan DR, Franke TF. Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci USA 1997; 94:11345-50.
18. Mitkevich VA, Tchurikov NA, Zelenikhin PV, Petrushanko IY, Makarov AA, Ilinskaya ON. Binase cleaves cellular noncoding RNAs and affects coding mRNAs. FEBS J 2010; 277:186-96.
19. Zhao H, Ardelt B, Ardelt W, Shogen K, Darzynkiewicz Z. The cytotoxic ribonuclease onconase targets RNA interference (siRNA). Cell Cycle 2008; 7:3258-61.
20. Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib. Clin Pharmacol Ther 2010; 87:543-52.
21. Lennartsson J, Ronnstrand L. The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets 2006; 6:65-75.
22. Quintas-Cardama A, Cortes J. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy? Curr Oncol Rep 2009; 11:337-45.
23. Abraham AT, Lin JJ, Newton DL, Rybak S, Hecht SM. RNA cleavage and inhibition of protein synthesis by bleomycin. Chem Biol 2003; 10:45-52.
24. Tanaka Y, Kurata M, Togami K, Fujita H, Watanabe N, Matsushita A, et al. Chronic eosinophilic leukemia with the FIP1L1-PDGFRalpha fusion gene in a patient with a history of combination chemotherapy. Int J Hematol 2006; 83:152-5.
25. Pectasides D, Nikolaou M, Pectasides E, Koumarianou A, Valavanis C, Economopoulos T. Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma. Anticancer Res 2008; 28:2317-20.
26. Coskun HS, Goksu SS, Sahin M, Alanoglu G. Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor. Med Oncol 2008; 25:110-2.
27. Ita M, Halicka HD, Tanaka T, Kurose A, Ardelt B, Shogen K, Darzynkiewicz Z. Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines. Cancer Biol Ther 2008; 7:1104-8.
28. Schulga A, Kurbanov F, Kirpichnikov M, Protasevich I, Lobachev V, Ranjbar B, et al. Comparative study of binase and barnase: experience in chimeric ribonucleases. Protein Eng 1998; 11:773-80.
29. Ilinskaya ON, Ivanchenko OB, Karamova NS, Kipenskaya LV. SOS-inducing ability of native and mutant microbial ribonucleases. Mut Res 1996; 354:203-9.
30. Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantitities of interleukin 2, 3, 4 or 5, using modified cDNA expressing vectors. Eur J Immunol 1988; 18:97-104.
31. Koopman BG, Reutelingsperger CPM, Kuijten GAM, Keehnen RMJ, Pals ST, van Oers MHJ. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84:1415-20.
32. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006; 1:1458-61.